.png)
.png)
Abzena launches EpiScreen® 2.0, a next-generation immunogenicity tool for de-risking the development of complex biologics
Abzena has announced the launch of its enhanced hashtag#bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical hashtag#immunogenicity in protein, antibody, and gene therapy therapeutics.
University of Oxford spin-out revealed as winner of ‘Golden Ticket’ programme for planetary health innovations
University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.
CHAIN Biotech collaborates with German Cancer Research Center on development of a novel oncology vaccine
CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV).
Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data
Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.
Coulter Partners top hires for VC & PE portfolio companies Q1-2024
Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.
Abzena announces major investment in bioconjugation and ADC capabilities in response to increasing industry demand
Abzena announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.
New £6.2 million partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
A new £6.2 million healthcare project has begun in Kenya to advance elimination of visceral leishmaniasis, a deadly parasitic disease found in Africa, the Americas, the Middle East and South-East Asia, which affects up to 90,000 children and vulnerable people globally.
New study explores how Switzerland can maintain its leading position in life science innovation
The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity Reports: “Sustaining a winning position”, an analysis of how Switzerland can continue to lead the life sciences sector in a shifting global market.
Data from Brainomix’s collaboration with AstraZeneca shows e-Lung better identifies lung fibrosis patients at risk of decline
Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix’s AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.
Eight things we learned about commercialising medical research at Imperial's 'All You Can Innovate' 2024
Why to channel Scottish polymath Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.